With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Over the weekend at the European Society for Medical Oncology’s annual meeting in Barcelona, cancer researchers unveiled results from scores of important clinical trials. You can read full stories ...

Warner Biddle and Christi Shaw, two prominent former executives at Gilead’s CAR-T division, will try to turn around an autoimmune cell therapy developer that’s lost most of its value since raising ...

Next-generation sequencing (NGS) is the future of GxP for biosafety and product characterization. This method of fast, sensitive, cost-efficient genetic sequencing can help evaluate viral content, ...

Final follow-up results suggest Opdivo and Yervoy could be close to a cure for some people with advanced melanoma, shifting how doctors administer follow-up care.

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Three drug startups collectively raised more than $700 million in initial public offerings Thursday, a flurry of activity after a largely fallow summer in which few biotechnology companies made the ...

Today, a brief rundown of news from Roche and Gilead Sciences, as well as updates from Eli Lilly, Biogen and GSK that you may have missed. Multibillion-dollar buyouts from Bristol Myers Squibb and ...

Months after winning approval of a new vaccine for respiratory syncytial virus, Moderna is acknowledging that wresting market share from its two competitors may be more difficult than it thought.